The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
ASML Holding NV (minority stake)
Advised the Supervisory Board of ASML on the establishment of a Customer Co-Investment Program including the issue of 23% equity stake and $1.7 billion of R&D funding
Assets owned by GlaxoSmithKline plc
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
Procaps Group
Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"
Portfolio of Towers from PLDT
Advising edotco Group, the leading pan-Asian telecom tower infrastructure company, on the acquisition of 2,973 towers from PLDT, one of the largest telecommunication service providers in the Philippines, through a sale and leaseback transaction
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Taro Pharmaceutical Industries
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
Hitachi's Automotive Lithium-Ion Battery Business
Advised Hitachi, a leading global industrial conglomerate, on the sale of its LiB business including Hitachi Vehicle Energy
Portfolio of Towers from PLDT
Advising Unity Digital Infrastructure Inc., a leading Philippine-based joint venture telecommunications infrastructure platform by Aboitiz InfraCapital and Partners Group, on the acquisition of 650 towers from PLDT, one of the largest telecommunication service providers in the Philippines, through a sale and leaseback transaction
Japan Medical Dynamic Marketing
Advising Mitsui Chemicals, one of the largest Japanese chemical companies, on the acquisition of a 30% stake in Japan Medical Dynamic Marketing, a leading orthopedic medical device manufacturer in Japan, held by NGK SPARK PLUG
Park Electrochemical (Electronics Business)
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
Equity stake in Bupa Arabia
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
Rico
Advised the founding shareholders of Rico, a leading independent online investment platform in Brazil, on its 100% sale to XP Investimentos, a Brazilian investment firm
euNetworks Group Limited
Advised euNetworks Group Ltd, a Singapore listed operator of a fibre telecommunications network in Europe, on a repurchase at a discount of the majority of its outstanding convertible bonds, financed by a placement and rights issue
Portal de Documentos
Advised Portal de Documentos, a provider of digital solutions for participants in the credit cycle, with procedures for credit collection, renegotiation and servicing of vehicle and real estate loans, on its 100% sale to Brazil’s Stock Exchange, B3 S.A. – Brasil, Bolsa, Balcão
WEX Inc. - Brazilian Operations/Subsidiary
Advised WEX Inc., a leading fleet and B2B payments company, on the divestiture of its Brazilian subsidiary to Vila Rica Capital.
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
Policard
Advised Policard, one of the largest electronic payment companies in Brazil, on the combination of its business with the Brazilian operations of Groupe Up, one of the leading employee benefits, public, social and loyalty programs providers in the world
Elavon do Brasil
Advised Minneapolis-based US Bancorp, the fifth largest commercial bank in the United States, and the parent company of Elavon, Inc., in the sale of its 50.1 percent majority stake in São Paulo-based, Elavon do Brasil to Stone Pagamentos, a local market, privately-held merchant acquirer.
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Brasil/CT
Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Recepta Biopharma
Advised Recepta Biopharma on a capital raise